

Emerging small molecule antivirals may fit neatly into C

Drugs and Therapy Perspectives

38, 112-126

DOI: [10.1007/s40267-022-00897-8](https://doi.org/10.1007/s40267-022-00897-8)

Citation Report

#	ARTICLE	IF	CITATIONS
2	Peptide-Based Strategies Against SARS-CoV-2 Attack: An Updated In Silico Perspective. <i>Frontiers in Drug Discovery</i> , 2022, 2, .	1.1	6
3	Paxlovid: Mechanism of Action, Synthesis, and In Silico Study. <i>BioMed Research International</i> , 2022, 2022, 1-16.	0.9	56
4	Simultaneous determination of nirmatrelvir and ritonavir in human plasma using LC-MS/MS and its pharmacokinetic application in healthy Chinese volunteers. <i>Biomedical Chromatography</i> , 2022, 36, .	0.8	16
5	Developing New Treatments for COVID-19 through Dual-Action Antiviral/Anti-Inflammatory Small Molecules and Physiologically Based Pharmacokinetic Modeling. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8006.	1.8	3
6	Is long COVID the next global health crisis?. <i>Journal of Global Health</i> , 0, 12, .	1.2	17
7	Would the Development of a Multitarget Inhibitor of 3CLpro and TMPRSS2 be Promising in the Fight Against SARS-CoV-2?. <i>Medicinal Chemistry</i> , 2023, 19, 405-412.	0.7	1
8	Nirmatrelvir plus ritonavir in COVID-19: a profile of its use. <i>Drugs and Therapy Perspectives</i> , 2023, 39, 41-47.	0.3	5
9	Design of hACE2-based small peptide inhibitors against spike protein of SARS-CoV-2: a computational approach. <i>Structural Chemistry</i> , 2023, 34, 1843-1856.	1.0	0
10	Targeting neutrophils extracellular traps (NETs) reduces multiple organ injury in a COVID-19 mouse model. <i>Respiratory Research</i> , 2023, 24, .	1.4	17
12	Natural Products: Exploring Potential Against SARS CoV2. , 2024, , 441-474.		0